Allergan Gedeon Richter Plc. to Present Data from Cariprazine Trials at ECNP Annual Meeting in Amsterdam

Allergan plc

and Gedeon Richter Plc today announced they will present data on the investigational drug cariprazine in patients with schizophrenia and acute mania in bipolar I disorder during the 28th European College of Neuropsychopharmacology (ECNP) annual congress in Amsterdam, to be held August 29 – September 1, 2015. Data presented include the first detailed results of cariprazine for the potential treatment of schizophrenia patients with predominant negative symptoms. Richter Poster Mon., August 31, 12:15-1:45 pm CEST Cariprazine as Monotherapy for the Treatment of Schizophrenia Patients with Predominant Negative Symptoms: A Double-Blind, Active Controlled Trial (abstract #P.3.d.053), authored by Debelle, M., Nemeth, G., Szalai, E., Szatmari, B., Harsanyi, J., Barabassy, A., Laszlovszky, I. Allergan and Richter Posters Mon., August 31, 12:15-1:45 pm CEST Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Trial (abstract #P.3.d.057), authored by Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W.W., Lieberman, J.A. Categorical Improvement Across Mania Symptoms: Pooled Analyses of Cariprazine Phase II/III Trials (abstract #P.2.d.014), authored by Durgam, S.,